Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC

Lung cancer is the leading cause of cancer-associated mortality, worldwide. For this reason, novel therapies are required for the treatment of this devastating disease. Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), which is overexpressed in a variety of solid tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yang, Yang, Jie, Ding, Manhua, Li, Liantao, Lu, Zheng, Zhang, Qing, Zheng, Junnian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103927/
https://www.ncbi.nlm.nih.gov/pubmed/27899989
http://dx.doi.org/10.3892/ol.2016.5081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103927/
https://www.ncbi.nlm.nih.gov/pubmed/27899989
http://dx.doi.org/10.3892/ol.2016.5081

Ejemplares similares